Inclusion Criteria:

• Body Mass Index (BMI) ≥ 18.0 to < 35 kg/m^2.
• HIV-1 infected on antiretroviral therapy (ART) for at least 12 months prior to screening and on current ART regimen for at least 12 weeks prior to screening.
• Meets HIV-specific laboratory parameters as below:
  • Plasma HIV-1 RNA below lower limit of detection (LLOD) at screening and at least 6 months prior to screening;
  • CD4+ T cell count ≥ 500 cells/uL at screening and at least once during the 12 months prior to screening;
  • CD4+ T cell nadir of ≥ 350 cells/uL during chronic infection.
• Willing to undergo ART interruption.
• Agrees to use an effective barrier method of protection (male and/or female condoms) during sexual activity for protection against HIV-1 transmission throughout the entire study

Exclusion Criteria:

• Known resistance to ≥ 2 classes of ART.
• History of AIDS-defining illness.
• Active or suspected malignancy or history of malignancy (other than basal cell skin cancer or cervical carcinoma in situ) in the past 5 years.
• History of or active immunodeficiency (other than HIV).
• Active autoimmune disease or history of autoimmune disease that has required systemic treatment.
• Prior receipt of immunomodulatory or immunosuppressive (including intravenous infusion or oral steroids at any dose, but excluding steroids that are inhaled, topical or by local injection) therapy within 6 months prior to the first dose of study drug.
• Current hepatitis B virus or hepatitis C virus infection.
• Female participants must not be pregnant, breastfeeding, or considering becoming pregnant during the study.